HealthTree Podcast for Multiple Myeloma HealthTree Podcast for MM

Dr. Morie Gertz joins the HealthTree Podcast for Multiple Myeloma to share the challenges, treatments and futures of AL amyloidosis and invites amyloidosis patients to join this survey about their diagnosis experience.

Dr. Ola Landgren shares a clinical trial about smoldering myeloma. Join the REVIVE trial study for high-risk smoldering myeloma study here. 

He also share about his research partnership with HealthTree on a personalized medicine study that creates a computerized model of risk prediction and treatment recommendations for newly diagnosed patients. 

This is a study that is open to all myeloma patients regardless of where they are being treated. The only involvement by patients is to sign a consent form and connect their medical records which requires less than 5 minutes of participation. 

Dr. Clifton Mo of Dana Farber Cancer Institue shares a multitude of tools available in the myeloma toolbox. This includes all of the "standard of care" drugs that we are familiar with such as immunomodulators, proteasome inhibitors, steroids, monoclonal antibodies as well as tools in development. 

He reviews triplet combo treatment options at first relapse and his preference to use Kyprolis in the mix, especially when given a more aggressive myeloma. 

Dr. Mo explains how antibody drug conjugates (ADCs) work and how the first ADC, BLENREP, may be making a comeback. He shares how dexamethasone can be reduced or stopped under certain conditions. He explains BCL-2 inhibitors like venetoclax and how they are making their way through clinical trials. 

Dr. Mo describes celmods and how they work and are a promising new class of drugs. He also described how an XPO1 inhibitor called selinexor is being used both with the celmods  and alone as an agent that works well for higher risk myeloma. 

This shows myeloma patients how fortunate we are to have these tools available and speaks to the importance of having a myeloma specialist on your team who can help you make treatment decisions. This can be done alone or in partnership with your local oncologist. There is data that shows that having a specialist on year team leads to longer life. 

Learn how bispecific antibodies are being used in multiple myeloma care and how physicians are helping patients manage side effects using new approaches like fixed-duration therapy.

The year 2024 brings new promise in multiple myeloma with a wide variety of treatment options avaiable for both newly diagnosed and relapsed/refractory patients. Learn about the progress being made and the very latest in determining risk at diagnosis, strategies for smoldering myeloma patients, optimal treatments for newly diagnosed patients, things to consider at first relapse and beyond. Dr. Robert Orlowski will review advances in CAR T therapies, bispecific antibodies, targeted therapies and combination approaches and clinical trials to watch as the research continues advancing at a rapid pace in myeloma. 

Thanks to our episode sponsor, GSK.

CAR T therapy is a highly effective treatment for myeloma patients, even in highly relapsed multiple myeloma. In today's show we will hear from Luciano Costa, MD of the University of Burmingham who will do a deep dive into CAR T therapy in multiple myeloma to discuss how CAR T availability is improving, how CAR T is being tested in earlier lines of therapy, side effects to consider, new CAR T targets, combo CAR Ts, maintenance therapy post-CAR T, open CAR T clinical trials and various new forms CAR T variants like NK CAR Ts. Join us for this important show on one of the most impressive therapies ever developed in myeloma! 

Thanks to our episode sponsor, 

Menarini Silicon Biosystems